Psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) confirmed that the first patient has been dosed in its Phase 1b study assessing the interaction between selective serotonin reuptake inhibitors (SSRIs) and proprietary lead DMT candidate SPL026 in patients with Major Depressive Disorder (MDD).
Medicine Man Technologies operating as Schwazze, (OTCQX: SHWZ) (NEO:SHWZ), a vertically integrated, multi-state operating cannabis company with assets in Colorado and New Mexico, reached company milestone of
As the cannabis industry holds its breath while waiting to hear if marijuana banking reform will be part of a must-pass omnibus spending bill, James Hagedorn, a CEO of the lawn care giant Scotts Miracle-Gro (NYSE: SMG) shared
Psychedelics company Clearmind Medicine Inc. (NASDAQ: CMND) aims to bring its proprietary compound, CMND-100, to clinical trials while developing additional proprietary psychedelic compounds for next-generation novel drug candidates, according to CEO Adi Zuloff-Shani.